FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of m

[News]

Eli Lilly and Company today announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer.

More... (http://www.news-medical.net/news/20151008/FDA-grants-Breakthrough-Therapy-Designation-to-Lillys-abemaciclib-for-treatment-of-metastatic-breast-cancer.aspx)